Campalani E - Search Results

1

Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin.

Campalani E, Allen MH, Fairhurst D, Young HS, Mendonca CO, Burden AD, Griffiths CE, Crook MA, Barker JN, Smith CH. Campalani E, et al. Br J Dermatol. 2006 Feb;154(2):345-52. doi: 10.1111/j.1365-2133.2005.06950.x. Br J Dermatol. 2006. PMID: 16433808

2

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms.

Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, Worthington J, Griffiths CE. Warren RB, et al. Among authors: campalani e. Br J Dermatol. 2009 Feb;160(2):438-41. doi: 10.1111/j.1365-2133.2008.08898.x. Epub 2008 Oct 25. Br J Dermatol. 2009. PMID: 19016697 Free PMC article.

3

Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.

Young HS, Summers AM, Read IR, Fairhurst DA, Plant DJ, Campalani E, Smith CH, Barker JN, Detmar MJ, Brenchley PE, Griffiths CE. Young HS, et al. Among authors: campalani e. J Invest Dermatol. 2006 Feb;126(2):453-9. doi: 10.1038/sj.jid.5700096. J Invest Dermatol. 2006. PMID: 16385345 Free article.

4

Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis.

Campalani E, Arenas M, Marinaki AM, Lewis CM, Barker JN, Smith CH. Campalani E, et al. J Invest Dermatol. 2007 Aug;127(8):1860-7. doi: 10.1038/sj.jid.5700808. Epub 2007 Apr 5. J Invest Dermatol. 2007. PMID: 17410198 Free article.

5

Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis.

Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, Worthington J, Griffiths CE. Warren RB, et al. Among authors: campalani e. J Invest Dermatol. 2008 Aug;128(8):1925-9. doi: 10.1038/jid.2008.16. Epub 2008 Feb 7. J Invest Dermatol. 2008. PMID: 18256692 Free article.

6

British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology.

Ormerod AD, Campalani E, Goodfield MJ; BAD Clinical Standards Unit. Ormerod AD, et al. Among authors: campalani e. Br J Dermatol. 2010 May;162(5):952-63. doi: 10.1111/j.1365-2133.2010.09755.x. Br J Dermatol. 2010. PMID: 20423353 Review. No abstract available.

7

A simple method to assess severity of polymorphic light eruption.

Palmer RA, van de Pas CB, Campalani E, Walker SL, Young AR, Hawk JL. Palmer RA, et al. Among authors: campalani e. Br J Dermatol. 2004 Sep;151(3):645-52. doi: 10.1111/j.1365-2133.2004.06100.x. Br J Dermatol. 2004. PMID: 15377352

8

Paraneoplastic hypertrichosis lanuginosa acquisita: a delayed presentation in quiescent chronic lymphocytic leukaemia.

Worsnop F, Campalani E. Worsnop F, et al. Among authors: campalani e. Clin Exp Dermatol. 2014 Jul;39(5):669-70. doi: 10.1111/ced.12310. Epub 2014 Apr 9. Clin Exp Dermatol. 2014. PMID: 24712899 No abstract available.

9

Lupus vulgaris due to Mycobacterium bovis bacillus Calmette-Guérin (BCG) at the site of previous BCG vaccination.

Walker SL, Lozewicz S, Sood R, Mann TA, Campalani E, Hubbard VG. Walker SL, et al. Among authors: campalani e. Clin Exp Dermatol. 2009 Oct;34(7):e213-5. doi: 10.1111/j.1365-2230.2008.03057.x. Epub 2008 Dec 22. Clin Exp Dermatol. 2009. PMID: 19120384 No abstract available.

10

A boy with persistent 'atopic eczema' resistant to conventional topical therapies.

Campalani E, Cerio R, Paige D. Campalani E, et al. Clin Exp Dermatol. 2009 Dec;34(8):927-8. doi: 10.1111/j.1365-2230.2008.03085.x. Clin Exp Dermatol. 2009. PMID: 20055884 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14 results

Search Page